Angiotensin-converting enzyme inhibitor-associated angioedema in a cohort of Caucasian patients: from bed to bench.
Angiotensin-converting enzyme inhibitor-associated angioedema (ACEI-AAE) occurs in 0.1%-0.7% of patients treated with ACEIs. While previous research suggests that angioedema attacks result from increased vascular permeability, the pathogenesis is not completely understood. Objective: This study aimed to describe the clinical, genetic, and laboratory parameters of ACEI-AAE patients and to investigate the role of vascular endothelial growth factors A and C (VEGF-A and VEGF-C), angiopoietins 1 and 2 (Ang1/Ang2), and secretory phospholipases A2 (sPLA2) in ACEI-AAE pathogenesis. The clinical and laboratory data of ACEI-AAE patients were collected from two angioedema centers. Healthy volunteers and ACEI-treated patients without angioedema were enrolled to compare concentrations of laboratory parameters. Genetic analyses to detect mutations in SERPING1, ANGPT1, PLG, and F12 genes were performed in a subset of patients. 51 patients (57% male) were diagnosed with ACEI-AAE. The average time to symptom onset from the start of ACEI therapy was 3 years (range 30 days-20 years). The most commonly affected sites were lips (74.5%), tongue (51.9%), and face (41.2%). Switching from ACEIs to sartans was not associated with an increased risk of angioedema in patients with a history of ACEI-AAE. VEGF-A, VEGF-C, and sPLA2 plasma levels were higher in ACEI-AAE patients than in the controls. Ang1/2 concentrations were not modified. No mutations were detected in the genes analyzed. Our data suggest that sartans can be a safe therapeutic alternative in ACEI-AAE patients. Increased concentrations of VEGF-A, VEGF-C, and sPLA2 in ACEI-AAE patients suggest a possible role of these mediators in ACEI-AAE pathogenesis.